News

Biocon launches bone therapy biosimilars Bosaya, Aukelso in US marketBosaya, a biosimilar to Prolia, and Aukelso, a biosimilar to Xgeva, are now available by prescription across the country through specialty pharmacies and healthcare providers, said the company.By Navneet Singh  April 7, 2026, 4:50:33 PM IST (Published)2 Min ReadBiocon Limited on Tuesday, April 7,  announced the commercial launch of Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) in the United States.

As per the exchange filling, Bosaya, a biosimilar to Prolia, and Aukelso, a biosimilar to Xgeva, are now available by prescription across the country through specialty pharmacies and healthcare providers.

The biopharmaceutical firm added that both products were previously approved and granted interchangeable designation by the US Food and Drug Administration in September 2025, enabling substitution at the pharmacy level in line with state laws.

Shreehas Tambe, CEO & Managing Director, Biocon Limited, said, “The US introduction of Bosaya and Aukelso marks a strategic expansion of our biosimilars portfolio, building on our established leadership in oncology and immunology. These therapies broaden access to high-quality, affordable treatment options for patients living with serious bone conditions."

He added, "This milestone underscores Biocon’s strength as a portfolio development engine and our focus on building the world’s most scalable access platform—advancing life-changing medicines for patients and health systems across the United States and around the world.”

Also Read: AC players feel the heat as unseasonal rain pours cold water on summer demand

Biocon stated that Denosumab-based treatments are widely used in bone health, including for osteoporosis and cancer-related bone complications. In 2024, denosumab products recorded about $5 billion in US sales, highlighting strong demand for accessible treatment options.

Shares of Biocon Limited ended at ₹340.25 on the NSE on April 7, down ₹14.75 or 4.15% from the previous close, reflecting a notable decline in the stock during the day’s trading session.

Also Read: Trading ban upends SBI’s $5 billion bets against rupeeContinue ReadingTagsBioconUSAUSFDA